Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
MEDIMMUNE INC (MEDI) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/27/2007 8-K Quarterly results
06/18/2007 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement, Notice of...
Docs: "Notice of Fundamental Change and Make-Whole Fundamental Change",
"Press Release by MedImmune, Inc."
06/01/2007 8-K Changes in Control of Registrant, Departure of Directors or Principal Officers; Election of Directors; Appointment of Princip...
Docs: "SUCCESSFUL ASTRAZENECA TENDER OFFER FOR MEDIMMUNE SHARES"
05/08/2007 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation under an Off-Balance Sheet Arrangement, Material ...
Docs: "Notice of Convertibility and Make-Whole Fundamental Change",
"Contacts"
04/30/2007 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS FINANCIAL RESULTS FOR 2007 FIRST QUARTER"
04/23/2007 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among AstraZeneca PLC, AstraZeneca Biopharmaceuticals Inc. and MedImmune, Inc",
"AstraZeneca to acquire MedImmune for $58 per share in a fully recommended, all-cash transaction with a total enterprise value of $15.2 billion Acquisition delivers AstraZeneca biologics ambition faster Creates a leading, fully-integrated biotechnology business within AstraZeneca with critical mass in research, development, regulatory and manufacturing with global sales reach Significantly expands product pipeline by adding 45 projects including 2 late-stage products and a blockbuster marketed monoclonal antibody, Synagis Summary AstraZeneca PLC today announced that it has entered into a definitive agreement to acquire MedImmune, Inc. , in an all-cash transaction. Under the terms of the agreement, which has unanimous MedImmune Board support, AstraZeneca will acquire all of the fully diluted shares of MedImmune common stock at a price of $58 per share, for a total consideration of approximately $15.6 billion . The acquisition of MedImmune significantly accelerates AstraZeneca's biologics strategy. The combination of MedImmune with AstraZeneca's wholly-owned subsidiary Cambridge Antibody Technology will create a world-class, fully integrated biologics and vaccines business within the AstraZeneca Group with critical mass in research, development, regulatory, manufacturing and global sales and marketing reach. MedImmune is a world-leading, profitable, biotechnology company with a record of proven success with revenue in 2006 of $1.3bn, profit before tax of $75m and gross assets of $3.0bn. The acquisition extends AstraZeneca's R&D science base to allow it to address novel drug targets through 3 key technological approaches: small molecules, biologics and, for the first time, vaccines. Overall, the combination of MedImmune with AstraZeneca's existing capabilities will be capable of delivering a greater number of new biologic products to bring benefit to patients in AstraZeneca's prioritised disease areas. The deal is expected to close in June 2007. Highlights and acquisition benefits R&D capability"
04/12/2007 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIMMUNE EXPLORES STRATEGIC ALTERNATIVES"
04/11/2007 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE ANNOUNCES PRELIMINARY RESULTS FOR 2007 FIRST QUARTER Company Invites Investors to Participate in First-Quarter 2007 Earnings Conference call on May 3, 2007"
04/03/2007 8-K Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers, Financial Statements ...
Docs: "MEDIMMUNE ANNOUNCES ADDITION OF ROBERT H. HOTZ TO BOARD OF DIRECTORS"
02/16/2007 8-K Regulation FD Disclosure
02/07/2007 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS FINANCIAL RESULTS FOR 2006"
12/13/2006 8-K Regulation FD Disclosure
11/13/2006 8-K Other Events, Financial Statements and Exhibits
10/26/2006 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS FINANCIAL RESULTS FOR 2006 THIRD QUARTER AND NINE-MONTH PERIOD"
08/31/2006 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "1"
07/24/2006 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS 2006 SECOND-QUARTER AND SIX-MONTH FINANCIAL RESULTS"
07/05/2006 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Indenture related to the Convertible Senior Notes, due 2011, between MedImmune Inc. and Bank of New York, as trustee",
"Indenture related to the Convertible Senior Notes, due 2013, between MedImmune Inc. and Bank of New York, as trustee",
"Registration Rights Agreement, among MedImmune Inc., UBS Securities LLC and Merrill Lynch, Pierce Fenner & Smith Incorporated",
"MEDIMMUNE CLOSES SALE OF $1.15 BILLION CONVERTIBLE SENIOR NOTES"
06/26/2006 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIMMUNE TO OFFER $1 BILLION CONVERTIBLE SENIOR NOTES",
"MEDIMMUNE PRICES $1 BILLION CONVERTIBLE SENIOR NOTES"
04/20/2006 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS FINANCIAL RESULTS FOR FIRST QUARTER 2006"
03/01/2006 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "EMPLOYMENT AGREEMENT"
02/02/2006 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS 2005 FINANCIAL RESULTS"
01/09/2006 8-K Termination of a Material Definitive Agreement
12/15/2005 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "EMPLOYMENT AGREEMENT",
"ANNEX A",
"Employment Agreement entered into by and between the Company and Wayne T. Hockmeyer, Ph.D."
12/12/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "1"
10/20/2005 8-K Other Events, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS 2005 THIRD QUARTER AND NINE-MONTH FINANCIAL RESULTS"
10/06/2005 8-K Entry into a Material Definitive Agreement
08/31/2005 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "MEDIMMUNE AMENDS U.S. CO-PROMOTION AGREEMENT FOR SYNAGIS ® WITH ABBOTT"
07/21/2005 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "MEDIMMUNE REPORTS 2005 SECOND QUARTER AND SIX-MONTH FINANCIAL RESULTS"
06/30/2005 8-K Entry into a Material Definitive Agreement
05/24/2005 8-K Entry into a Material Definitive Agreement, Departure of Directors or Principal Officers; Election of Directors; Appointment ...
04/21/2005 8-K Quarterly results
Docs: "FINANCIAL RESULTS FOR FIRST QUARTER 2005"
04/15/2005 8-K Other Events
04/06/2005 8-K Resignation/termination of a director
Docs: "MEDIMMUNE ANNOUNCES ADDITION OF GEORGE M. MILNE, JR., PH.D. TO BOARD OF DIRECTORS"
03/03/2005 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CO-PROMOTION RIGHTS FOR NUMAX WITH ABBOTT"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy